My position's no different to CHM's. As I said in my other post, it is unresolved (the ligand is not known), it is of increasing importance, just not of pressing importance for the reasons I've stated above and in my other post. It may help resolve which other cancers are most targetable by this therapy in the future and add granularity to patient stratification, but neither of those things are of pressing importance right now.
I would imagine they didn't mention it in the ASX announcement for this very reason - it's not particularly important right now. Easily resolvable going forward.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)